330 related articles for article (PubMed ID: 9692667)
1. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
Barcia JP
Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
[TBL] [Abstract][Full Text] [Related]
2. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
3. Reversible dilated cardiomyopathy related to amphotericin B therapy.
Danaher PJ; Cao MK; Anstead GM; Dolan MJ; DeWitt CC
J Antimicrob Chemother; 2004 Jan; 53(1):115-7. PubMed ID: 14657095
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review.
Rowles DM; Fraser SL
Clin Infect Dis; 1999 Dec; 29(6):1564-5. PubMed ID: 10585814
[TBL] [Abstract][Full Text] [Related]
5. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
6. Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs.
Krawiec DR; McKiernan BC; Twardock AR; Swenson CE; Itkin RJ; Johnson LR; Kurowsky LK; Marks CA
J Am Vet Med Assoc; 1996 Dec; 209(12):2073-5. PubMed ID: 8960189
[TBL] [Abstract][Full Text] [Related]
7. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
Winston DJ; Schiller GJ
Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
[No Abstract] [Full Text] [Related]
8. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
Sharkey PK; Graybill JR; Johnson ES; Hausrath SG; Pollard RB; Kolokathis A; Mildvan D; Fan-Havard P; Eng RH; Patterson TF; Pottage JC; Simberkoff MS; Wolf J; Meyer RD; Gupta R; Lee LW; Gordon DS
Clin Infect Dis; 1996 Feb; 22(2):315-21. PubMed ID: 8838189
[TBL] [Abstract][Full Text] [Related]
9. Acrocyanosis developed with amphotericin B deoxycholate but not with amphotericin B lipid complex.
Ozaras R; Yemisen M; Mete B; Mert A; Ozturk R; Tabak F
Mycoses; 2007 May; 50(3):242. PubMed ID: 17472626
[No Abstract] [Full Text] [Related]
10. Severe and common side-effects of amphotericin B lipid complex (Abelcet).
Ringdén O; Jønsson V; Hansen M; Tollemar J; Jacobsen N
Bone Marrow Transplant; 1998 Oct; 22(7):733-4. PubMed ID: 9818706
[No Abstract] [Full Text] [Related]
11. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.
Collazos J; Martínez E; Mayo J; Ibarra S
Clin Infect Dis; 2001 Oct; 33(7):E75-82. PubMed ID: 11528589
[TBL] [Abstract][Full Text] [Related]
12. Fatal fat embolism following amphotericin B lipid complex injection.
Tolentino LF; Tsai SF; Witt MD; French SW
Exp Mol Pathol; 2004 Dec; 77(3):246-8. PubMed ID: 15507243
[TBL] [Abstract][Full Text] [Related]
13. Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate.
Garnacho-Montero J; Ortiz-Leyba C; García Garmendia JL; Jiménez Jiménez F
Clin Infect Dis; 1998 Apr; 26(4):1016. PubMed ID: 9564508
[No Abstract] [Full Text] [Related]
14. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
Wiley JM; Seibel NL; Walsh TJ
Pediatr Infect Dis J; 2005 Feb; 24(2):167-74. PubMed ID: 15702047
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
Wingard JR
Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
Walsh TJ; Seibel NL; Arndt C; Harris RE; Dinubile MJ; Reboli A; Hiemenz J; Chanock SJ
Pediatr Infect Dis J; 1999 Aug; 18(8):702-8. PubMed ID: 10462340
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
[TBL] [Abstract][Full Text] [Related]
19. An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections.
Myint H; Kyi AA; Winn RM
J Antimicrob Chemother; 1998 Mar; 41(3):424-6. PubMed ID: 9578177
[No Abstract] [Full Text] [Related]
20. Respiratory distress secondary to both amphotericin B deoxycholate and lipid complex formulation.
Rolland WA; Guharoy R; Ramirez L; Blair D; Medicis J; Khan U
Vet Hum Toxicol; 2000 Aug; 42(4):222-3. PubMed ID: 10928687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
